UNIVERSITY OF ALABAMA AT BIRMINGHAM
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1969-01-01
- Employees
- 2K
- Market Cap
- -
- Website
- http://www.uab.edu
Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- Biological: cetuximab
- First Posted Date
- 2004-08-09
- Last Posted Date
- 2013-04-12
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 110
- Registration Number
- NCT00005076
Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Lung Cancer
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2013-04-12
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 55
- Registration Number
- NCT00004186
- Locations
- 🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's Lymphoma
Phase 1
Completed
- Conditions
- Lymphoma
- Interventions
- Biological: sargramostim
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2013-04-12
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 48
- Registration Number
- NCT00004162
- Locations
- 🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
ISIS 2503 in Treating Patients With Metastatic and/or Locally Recurrent Colorectal Cancer
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2013-04-12
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 25
- Registration Number
- NCT00004193
- Locations
- 🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
Gemcitabine Plus Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Solid Tumor
Phase 1
Terminated
- Conditions
- Lung Cancer
- First Posted Date
- 2004-07-26
- Last Posted Date
- 2013-11-20
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 54
- Registration Number
- NCT00004159
- Locations
- 🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed
Phase 1
Completed
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 72
- Registration Number
- NCT00004160
- Locations
- 🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants
Phase 1
Withdrawn
- Conditions
- LymphomaLeukemia
- Interventions
- Biological: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2016-03-21
- Lead Sponsor
- University of Alabama at Birmingham
- Registration Number
- NCT00002956
- Locations
- 🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy
Phase 2
Completed
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 34
- Registration Number
- NCT00086736
- Locations
- 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy
Not Applicable
Withdrawn
- Conditions
- brca1 Mutation Carrierbrca2 Mutation CarrierOvarian Cancer
- Interventions
- Procedure: oophorectomy
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2013-08-22
- Lead Sponsor
- University of Alabama at Birmingham
- Registration Number
- NCT00084370
- Locations
- 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
Fenretinide in Treating Patients With Leukoplakia of the Mouth
- First Posted Date
- 2004-06-04
- Last Posted Date
- 2013-04-12
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 30
- Registration Number
- NCT00004161
- Locations
- 🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
© Copyright 2025. All Rights Reserved by MedPath